

## INDEX

---

Note: AS stands for ankylosing spondylitis.

Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

Clinical trials and studies are indexed under the acronym of the name.

3E (Evidence, Experts, Exchange) Initiative, 193-194

Abatacept, 244

cautions for pregnancy and lactation, 238

Acetaminophen (Tylenol), 204-205

Activities of daily living, 207-208

Acute anterior uveitis (AAU), 95-99, 96, 97

association with HLA-B27, 98-99, 119-121

referral to specialist, 208

treatment

TNF-inhibitors, 220

topical corticosteroids, 204

Acute phase reactants, 159t

Adalimumab (Humira), 225-227

approved indications

adults with active AS (FDA approval), 217

nr-axSpA (nonradiographic axial spondyloarthritis), EMA

approval for, 29-31, 217, 220-221

composition (monoclonal antibody), 217

cost-effectiveness of therapy, 281

dosage and administration, 225, 237t

efficacy, 225-227, 226

vs secukinumab, 258t

indications for, 227

inflammatory bowel disease with AS, 182t

treatment of active AS in adults unresponsive to other therapies, 217

treatment of nr-axSpA

EMA approval, 29-31, 217, 220-221

not approved by FDA, 31, 221

patient characteristics, 74t-75t

TB and other infections, 241

*Legionella pneumophila*, 242

Age of onset, 85-86, 92t

juvenile-onset AS, 95, 147

late-onset AS, 87

socioeconomic impact and, 277

- American College of Rheumatology (ACR), 295  
treatment recommendations, 15
- Amjevits (biosimilar for adalimumab/Humira), 231
- Anakinra, cautions for pregnancy and lactation, 238
- Analgesics, 177, 204-205  
cautions for, 205
- Anesthesia, 209
- Ankylosing hyperostosis (DISH), 125, 130t-131t
- Ankylosing spondylitis (AS). See also *specific topics*.  
about, 13-21  
assessment and monitoring, 157-174  
as axial spondyloarthropathy, 13, 14  
case series, 287-292  
classification criteria, 23-34, 72  
clinical features, compared to related SpAs, 92t-93t, 119  
differences from nonradiographic axial spondyloarthropathy (nr-axSpA), 72, 74t-75t  
disease activity scoring, 117, 165-166  
disease course and outcome  
  long-term successful management (case study), 289-292  
  predictors of, 107  
  time to radiographic changes/evidence, 147-148  
  variability in, 107-109  
early diagnosis, 147-156  
etiology, 49-70  
extra-articular manifestations, 95-106  
genetic associations, 15-16  
heterogeneity of, 67-69  
imaging of, 125-146  
laboratory findings, 117-124  
long-term successful management of (case study), 289-292  
medical alert card, 210, 212-213  
musculoskeletal manifestations, 85-94  
organizations, 293-295  
patient characteristics, 72, 74t-75t, 92t-93t  
  HLA-B27 positivity and, 67, 123t  
physical findings, 107-116  
physical limitations due to stiffened spine, 197, 198-200  
prevalence, 35-48  
prognosis, 282-283  
progression of axial spondyloarthritis to, 27-29, 72, 72, 80  
sequence of events in, 14  
socioeconomic impact, 277-286  
symptoms of. See *Symptoms*.  
treatment. See *Treatment*.
- Ankylosing spondylitis (AS) (*continued*)  
vs axial spondyloarthritis, 71-83. See also *Axial spondyloarthritis*.  
  with radiographic evidence of sacroiliitis, 72-80
- Ankylosing Spondylitis Disease Activity Scores (ASDAS), 117
- Ankylosing Spondylitis International Federation (ASIF), 293
- Ankylosing Spondylitis, Spondylitis, Spondylarthritis, and HLA-B27 (organization), 294
- Anorexia, 95
- Apremilast, 203-204
- ASAS (Assessment of Spondyloarthritis International Society), 293  
ASAS/EULAR treatment recommendations, 175-176, 193, 217  
ASAS/OMERACT, core domains for evaluation, 157-164, 158, 159t  
ASAS TNF inhibitor treatment recommendations, 217, 218-219  
ASAS20, ASAS50, ASAS70 response criteria, 166-169, 168t  
classification criteria, 13, 23-27, 31t, 81  
consensus statement on TNF inhibitor therapy, 217, 218-219, 234  
diagnosis algorithms, 152, 153  
disease activity scores (ASDAS), 117, 166, 167  
Health Index, 171  
response and remission criteria, 166-169, 168t  
website, 157, 161
- ASAS20, ASAS50, ASAS70 response criteria, 166-169, 168t
- ASDAS disease activity scores, 117, 166, 167  
  for TNF inhibitor therapy, 237t
- Asian populations  
  HLA-B27 subtype, 52-53, 119, 120t  
  prevalence of AS in, 38, 40, 44
- ASSERT trial, 259t
- Assessment and monitoring, 157-174  
  acute phase reactants, 159t  
  ASAS Disease Activity Score (ASDAS), 117, 166, 167  
  ASAS Health Index, 171  
  ASAS/OMERACT  
    core domains and set for evaluation, 158, 159t  
    core domains for clinical record keeping, 158, 163  
    core domains for evaluation of DC-ART, 158, 163-164  
    core domains for evaluation of SMARDs/physical therapy, 157-162, 159t  
  ASAS response criteria (ASAS20, 50, 75), 167-169, 168t  
  BASDAI, 165-166, 169-170  
  BASFI, 160-161, 160t  
  BASMI, 161, 162t  
  BASRI, 164

Assessment and monitoring (*continued*)

- clinical disease activity, 165-166
  - BASDAI, 165-166
- core domains, 158
- core set for evaluation, 159t
- criteria for response and remission, 166-172
- fatigue, 159t, 162
- HAQ (Health Assessments Questionnaire), 170
- mental health (depression), 171
- pain, 159t, 161
- PASS (Patient Acceptable Symptom Scale), 170-171
- patient global assessment, 162
- peripheral joints/entheses, 159t
- physical function, 159t, 160-161, 160t
- quality of life assessments, 170
- response and remission criteria, 166-172
- spine
  - BASRI (Bath Ankylosing Spondylitis Radiology Index), 164
  - imaging, 163-164, 164
  - mobility of, 159t, 161-162, 162t
  - modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), 163-164, 164
  - stiffness, 159t, 162
  - visual analogue scale (VAS), 165
  - work productivity, 171-172
- Assessment of Spondyloarthritis International Society. See *ASAS*.
- Assistive devices, 208
- ATLAS trial, 258t
- Autoimmunity, 17, 62-63, 66-67
  - HLA-B27 and, 60
  - TNF inhibitors and, 239t, 243
- Autoinflammation, 17
- Automobiles, driving, 207
- Axial spondyloarthritis (ax-SpA), 71-83. See also *Nonradiographic axial spondyloarthritis (nr-axSpA)*.
  - classification criteria, 13, 71. See also *Classification criteria*.
  - diagnostic algorithms, 151, 152, 153
  - early stage may be equivalent to nr-axSpA, 71-72
  - nonradiographic (nr-axSpA), 15, 27-29, 71
  - progression to AS, 27-29, 72, 72
  - with radiographic evidence of sacroiliitis, 72-80
  - subgroups, 73
  - treatment. See *Treatment*.
  - vs AS, 71-83
  - vs peripheral, 13, 14

Axial spondyloarthropathies. See *Axial spondyloarthritis (axSpA)*.  
Azathioprine, 238, 243

Back pain

- chronic, 15, 73, 85-86, 147
    - in diagnostic algorithms, 152, 153
    - as early symptom, 147
    - referral to rheumatologist, 152
  - in classification criteria, 23, 24t, 25t, 26t, 28t-29t
  - fractures and, 210
  - inclusion in clinical trials, 15
  - inflammatory (IBP), 73, 86, 148
  - new-onset, 210
  - sleep problems and, 95
- Bamboo spine, 127, 134-135
- BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), 165-166
- BASDAI50, 169-170
- BASFI (Bath Ankylosing Spondylitis Functional Index), 160-161, 160t
- downloadable questionnaire, 161
- questions, 160t
- scores, 161
- BASMI (Bath Ankylosing Spondylitis Metrology Index), 161, 162t
- BASRI (Bath Ankylosing Spondylitis Radiology Index), 164
- Bath Ankylosing Spondylitis Indexes. See *BASDAI*; *BASFI*; *BASMI*; *BASRI*.
- Bathrooms, 208
- Belimumab, cautions for pregnancy and lactation, 238
- Berlin Spine Scores, with secukinumab, 264-265
- Biologics targeting IL-17, 253-276. See also *Secukinumab*.  
agents
  - ixekizumab, 256
  - secukinumab, 256-275. See also *Secukinumab*.
    - approvals for treatment of AS, 256-257
    - dose and administration, 275, 275
    - efficacy, 244, 257-263
    - safety and tolerability, 263-274
  - animal models, 255
  - approvals for treatment of AS, 256
    - FDA, EMA, and NICE, 256
  - clinical studies, summary of, 255
  - T helper 17 (TH17) cells, 253

Biologics targeting IL-23, 244, 253  
   agents, ustekinumab, 244, 253-256  
   animal models, 255  
   clinical studies, summary of, 255  
 Biologics targeting TNF- $\alpha$ . See *TNF inhibitor therapy*.  
 Biosimilars (for TNF inhibitors), 230-231  
   Amjevits (for adalimumab/Humira), 231  
   Erelzi (for etanercept/Enbrel), 231  
   Inflectra (for infliximab/Remicade), 230  
 Bone. See also *specific bones and areas, eg, spine*.  
   loss, 18  
   orthopedic referrals, 208  
   osteitis, 13  
   osteoproliferation, 18, 19, 89-90  
   remodeling, 14, 90, 102-103  
 Bone density, increased with TNF inhibitors, 231, 234  
 Bone marrow edema (BME) scores, 260-261, 264-265  
 Bone scintigraphy, 142  
 Brodalumab (anti-IL-17RA), 256  
 Bromodomain inhibition of CBP/p300, 19  
 Bursae, 89  
  
 C-reactive protein (CRP), 72, 76t, 117, 235  
   in ASDAS, 166  
   assessment and monitoring, 117, 157, 180  
   level in women with AS, 235  
   as predictor of disease progression, 107, 220, 283  
   as predictor of mortality from AS, 283  
   as predictor of response to therapies, 220  
 Canada, prevalence of AS in, 45  
 Cancer (malignancies)  
   secukinumab and, 274  
   TNF inhibitors and, 239t, 242-243  
 Candida infections, 274  
 CARD9, 61  
 Cardiovascular morbidity, 100-101  
   complications after surgery, 210  
   NSAIDs and, 202  
   pacemakers, 210  
   referral to cardiologist, 208  
   secukinumab and, 274  
 Case studies, 287-292  
   HLA-B27 positivity, 287-288  
   long-term successful management of AS, 289-292  
   pseudoarthrosis, 288-289  
  
 Cauda equina syndrome, 96, 103, 116  
 CBP (CREB binding protein), bromodomain inhibition, 19  
 CBP30, 19  
 Celecoxib (Celebrex), 202  
 Certolizumab pegol (Cimizia), 230  
   approved indications  
     adults with active AS (FDA approval), 217  
     nr-axSpA (nonradiographic axial spondyloarthritis) (EMA approval), 29-31, 217, 220-221  
   composition of, 217  
   dosage and administration, 230, 237t  
   efficacy, 230, 232-233  
     vs secukinumab, 259t  
   indications for  
     treatment of active AS in adults unresponsive to other therapies, 217  
     treatment of nr-axSpA  
       EMA approved, 29-31, 217, 220-221  
       not approved by FDA, 31, 221  
   infections and, 240  
   patient characteristics, 74t-75t  
 Chemokines, 16  
 Chest wall  
   flattening of, 114  
   pain, 87, 109-111  
 Children, inheritance of AS, 205-207  
 China  
   HLA-B27 subtype, 52-53  
   prevalence of AS, 44  
 Chronic back pain. See *Back pain, chronic*.  
 Cimizia. See *Certolizumab*.  
 Classification criteria, 23-34  
   Amor Criteria, 23, 30t, 81  
     compared with ESSG, 24-27  
   ASAS, 13, 23-27, 31t, 81  
     accuracy of, 24-25  
     clinical trials and, 15, 150  
     inclusion of MRI, 150-151  
   definition of AS through, 23-27, 25t, 26t, 72  
   ESSG (European Spondyloarthritis Study Group) criteria, 23, 28-29t, 81  
     compared with Amor, 24-27  
   HLA-B27 status in, 24

Classification criteria (*continued*)

- imaging in, 13, 24, 24t-26t, 31t, 71, 73, 125, 126t
  - interpretation of, 150
  - time needed to achieve radiologic changes, 147-148
- inclusion of back pain in, 23, 26t
- lack of diagnostic criteria, 13, 23, 27
- misclassification, 27
- MRI in, 24, 27, 31t, 81-82, 150-151
- New York Classification Criteria, 23, 25t
  - modified New York (mNY) criteria, 13-15, 23, 26t, 71, 72-80, 125, 126t
    - radiologic grading for sacroiliitis, 125, 126t
  - for nonradiographic axial spondyloarthritis (nr-axSpA), 27-29
  - Rome criteria, 23, 24t
- Clinical presentation, 147-156. See also *Diagnosis*.
- Clinical record keeping, 157, 158, 163
- Clinical trials. See *specific trials by acronym of name*.
- Colchicine, 238
- Comorbidities, 95-106, 96
  - treatment of, 205
- Conventional (nonbiologic) therapy, 193-216
  - 3E Initiative recommendations, 193-194
  - combination of nonpharmacologic and pharmacologic treatment, 194
  - costs of, 281
  - driving automobiles, 207
  - medical alert card, 210, 212-213
  - nonpharmacologic management, 194-197
    - combined with pharmacologic treatment, 194
    - exercise and physical therapy, 195-197
    - patient education, 194-195
  - patient concerns and questions, 205-208
  - pharmacologic therapy, 197-205
    - analgesics and other medications, 204-205
    - biologic therapies
      - IL-17-targeting, 253-276
      - TNF inhibitors, 217-252
    - combined with nonpharmacologic treatment, 194
    - corticosteroids, 204
    - DMARDs, 202-204
    - NSAIDs, 197-202
  - referrals/consultations, 208
  - surgery, role of, 209-210

Corticosteroids, 204. See also *Glucocorticoids*.

- ASAS/EULAR treatment recommendations, 177
  - injections, 204
  - topical, 204
- Cosentyx. See *Secukinumab (Cosentyx)*.
- Costs of AS, 277-278, 279t
  - direct healthcare costs, 278, 279t
  - indirect costs, 278
- COX-2 inhibitors, 201, 202
- CREB binding protein, bromodomain inhibition, 19
- Crohn's disease (CD), 60, 65, 99
  - approved treatment agents, ustekinumab, 256
  - cautions concerning secukinumab, 271
- CRP. See *C-reactive protein (CRP)*.
- CT (computed tomography) imaging, 141, 142
- Cyclophosphamide, 238
- Cyclosporin, 238
- Cytokines, 19, 57, 61, 90, 253, 254
  - inhibition by secukinumab, 256

DC-ART. See *Disease-controlling anti-rheumatic treatment*.

- Dectin-1, 61
- Demyelination, 103
  - TNF inhibitors and, 239t
- Depression, 171, 208
- DEXA scans, 142
- Diagnosis. See also *specific topics*.
  - algorithms for, 152, 153
  - case study (HLA-B27 positivity), 287-288
  - criteria for, 236t
    - lack of specific criteria or markers, 13, 23, 27, 117, 147
  - delayed, 86-87, 147, 148
    - increased mortality associated with, 283
    - in women, 86-87, 148, 149, 151
  - early, 147-156
    - comprehensive approach, 71
    - difficulties of, 71
    - IBP, 147, 148
    - improved treatment response with, 82, 148
    - MRI and, 81-82
    - need for, 82, 148, 151
    - nonspecific nature of early symptoms, 147
    - radiographically normal SI joints and, 147-148
    - "red flags" in, 148, 149t
    - underdiagnosis, 81
    - women, 148, 149, 151

Diagnosis (*continued*)

- extra-articular manifestations, 95-106, 96
- history, 71, 150
  - family history, 150
- imaging, 125-146
  - AS presentation with normal SI joints, 147
  - differentiating DISH from AS, 125, 130t-131t
  - NRI, 150-151
- laboratory findings, 117-124
  - HLA-B27 testing, 117-121, 151
  - musculoskeletal manifestations, 85-94
  - number of features used in, 71
  - physical findings, 107-116, 150
  - uncertain, wait-and-see approach, 151
- Diclofenac (Voltaren), 201
- Diet, 205
- Diffuse idiopathic skeletal hyperostosis (DISH), 125, 130t-131t
- Disability-related issues, 207-208
- Disease activity. See also *Assessment and monitoring*.
  - ASDAS (ASAS Disease Activity Score), 117, 166, 167
  - assessment and monitoring, 157-174
  - BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), 165-166
  - classification as inactive, moderate, high, very high, 166, 167
  - criteria for, 236t
  - disease activity scores (ASDAS), 117, 165-166
  - hypotheses on, 278, 280
- Disease-controlling anti-rheumatic treatment (DC-ART)
  - ASAS/OMERACT core domains for evaluation, 158, 163-164
  - TNF- $\alpha$  inhibitors, 157
- Disease course and outcome, 282-283
  - long-term successful management (case study), 289-292
  - predictors of, 107
  - prognosis, 282-283
  - time to radiographic changes/evidence, 147-148
  - variability in, 107-109
- Disease remission, 169
- DISH (diffuse idiopathic skeletal hyperostosis), 125, 130t-131t
- DMARDs, 202-204
  - apremilast, 203-204
  - leflunamide, 203
  - methotrexate (MTX), 203
  - sulfasalazine (SSZ), 203
  - thalidomide, 203
- Douglas Functional Index, 160
- Driving automobiles, 207
- Early diagnosis. See *Diagnosis, early*.
- EMA (European Medicines Agency), 294
  - approval of secukinumab for treatment of AS, 19, 256
  - approval of TNF inhibitors for nr-axSpA, 29-31, 217, 220-221, 235
- Enbrel. See *Etanercept*.
- Enteropathic SpA, 92t-93t
  - uveitis and, 98
- Enthesitis, 13, 14, 85, 87
  - assessment and monitoring, 159t
  - IL-17 and, 254
  - MRI of, 142, 144-145
  - physical findings for diagnosis, 150
  - radiographic evidence, 88
- Environmental factors, 65-67
- Epigenetic inhibitors, 19
- ER-associated aminopeptidases (ERAP1 and 2), 65, 66
- ERAP1 and ERAP2, 65, 66
- Erelzi (biosimilar for etanercept/Enbrel), 231
- Erythrocyte sedimentation rate (ESR), 80, 100, 157, 159t, 181
- ESR (erythrocyte sedimentation rate), 80, 100, 157, 159t, 181
- Etanercept (Enbrel), 222
  - approved indications
    - adults with active AS (FDA approval), 217
    - nr-axSpA (nonradiographic axial spondyloarthritis) (EMA approval), 29-31, 217, 220-221
  - biosimilar for (Erelzi), 231
  - composition of, 217
  - dosage and administration, 222, 237t
  - efficacy, 222, 223
    - vs secukinumab, 258t
    - vs sulfasalazine (SSZ), 203
  - indications for
    - inflammatory bowel disease with AS, 182t
    - treatment of active AS in adults unresponsive to other therapies, v217
    - treatment of nr-axSpA (EMA approval), 29-31, 217, 220-221
  - patient characteristics, 74t-75t
  - TB and other infections, 241
- Ethnicity. See *Race/ethnicity*.
- Etiology, 49-70
  - disease heterogeneity, 67-69
  - genetic factors, 49-65
    - HLA-B27, 49-60
      - hypotheses for, 56-60
    - role of additional genes, 60-65, 62-63

## Etiology (*continued*)

- gut microbiome and, 57-60, 65-66
- non-genetic factors, 65-67
  - biomechanical stress, 67, 87
  - gut microbiome, 57-60, 65-66
  - infectious triggers, 66-67, 93t
- twin studies, 49

Etoricoxib, 201

EULAR. See *European League Against Rheumatism*.

European League Against Rheumatism (EULAR), 294

- ASAS/EULAR treatment recommendations, 175-176, 193

European Medicines Agency (EMA), 294

- approval of secukinumab for treatment of AS, 19, 256
- approval of TNF inhibitors for nr-axSpA, 29-31, 217, 220-221, 235

European populations

- familial occurrence of AS in, 68
- prevalence of AS in, 36t, 37t, 39
- prevalence of HLA-B27 in, 41, 42t, 118, 120t

European Spondyloarthropathy Study Group (ESSG) classification

- criteria, 23, 28-29t, 81

Exercise, 195-197, 283

- heated swimming pool, 196-197
- home exercise program, 196
- lifetime recommendation, 194
- physical limitations due to spinal stiffness, 197, 198-200
- sports activities, 196
- stiff back and, 196

Extra-articular manifestations, 95-106, 96

- acute anterior uveitis (AAU), 95-99, 96, 97
- cardiovascular morbidity, 100-101
- cauda equina syndrome, 96, 103, 116
- heart, 96
- inflammatory bowel disease (IBD), 99
- kidneys, 96
- and prognosis/mortality in AS, 283
- psoriasis, 96, 100

Eye problems. See *Acute anterior uveitis (AAU)*.

FABERE test, 107, 108-109

FACIT (Functional Assessment of Chronic Illness Therapy), 162

Family of AS patients, 205-206

Fatigue, 95

- assessment and monitoring, 159t, 162
- MFI and FACIT measures, 162

FDA (US Food and Drug Administration), 274, 294

Fractures

- new-onset back of neck pain and, 210
- osteoporotic, 87
- spinal, 90, 101-102, 102t, 210

Functional capacity. See *Physical function*.

Gait, 89

Gender

- age of onset of AS, 85
- IL-17/23 signaling pathways and, 253
- prevalence of AS, 74t, 76t, 80-81, 92t
- prevalence of nr-axSpA (nonradiographic axial spondyloarthropathy), 71, 72, 76t, 80-81, 235
- progression of axial spondyloarthropathies to AS, 27
- progression to radiographic evidence of sacroiliitis, 81-82
- speed of disease progression, 86-87, 88, 114

Genetic associations of AS, 15-19, 49-65, 254

- children in families with AS patient, 205-207
- HLA-B27, 15-16, 49-60
- IL-17 and IL-23, 255
- inflammatory genes, 16
- interleukins, 16-19, 18
- predisposing genes, 16
- role of additional genes, 60-65, 62-63

Glucocorticoids, 204

- local, 180
- as pregnancy- and lactation-compatible, 238
- systemic, 180
- treatment recommendations, 177, 180, 182t, 204

GO-RAISE trial, 259t

Golimumab (Simponi), 227

- composition (monoclonal antibody), 217
- dosage and administration, 227, 237t
- efficacy, 227, 228-229
- vs secukinumab, 259t

patient characteristics, 74t-75t

GRADE system, 176, 178, 179t

Gut inflammation, 16, 67-68, 99

IL-17 and TNF and, 254

Gut microbiome, 16, 18, 65-66

diet and, 205

HLA-B27 and, 57-60

Haida Indians, 41, 120t

Heart. See also *Cardiovascular morbidity*.  
 congestive heart failure, TNF inhibitors and, 239t, 243  
 postsurgical complications, 210

Hepatosplenic T-Cell lymphoma (HSTCL), 243

Heritability. See *Genetic associations of AS*.

Herpes zoster infection, 242

Hip arthritis with AS  
 hip arthroplasty, 181, 182t  
 treatment recommendations, 182t

Hip extension, maintaining, 195

Hip joints, 88-89, 111-113, 113  
 assessment and monitoring, 159t  
 hip arthroplasty/replacement, 181, 209

HLA-B27, 49-60  
 alleles and subtypes, 52-53, 53  
 amino acid differences, 53, 54, 55  
 antigen-binding cleft, 49, 50-51  
 amino acid differences in, 54, 55  
 association with AS, 13, 15-16, 49-60, 92t, 117-118, 118t  
 age of AS onset, 85  
 characteristics of HLA-B27—positive patients, 67, 123t  
 children, inheritance concerns, 205-207  
 in diagnostic algorithms, 152, 153  
 homozygous individuals, 49  
 hypotheses for, 56-60  
 arthritogenic peptide hypothesis, 56-57  
 auto-antigenicity, 60  
 gut microbiota, 57-60  
 self-association and misfolding, 56-57, 58-59, 64  
 not a prerequisite for AS, 49, 67-68  
 with radiographically normal SI joints, 147-149  
 classification criteria and, 24  
 diagnosis and, 152, 153  
 case study, 287-288  
 heavy and light chains, 50-51, 56  
 misfolded proteins, 56, 57, 58-59, 64  
 organization for (resource), 294  
 prevalence of, 38, 41-44, 42t-43t, 92t, 117, 119  
 in Americas, 45  
 in AS, vs in nr-axSpA, 76t  
 in European populations, 37t, 42t, 118, 120t  
 probability reasoning and, 119, 122-123  
 race/ethnicity and, 13, 41, 42t-43t, 52-53, 54, 55  
 worldwide association, 118, 118t, 119, 120t

HLA-B27 (*continued*)  
 rheumatoid consultation, referral for, 121, 152  
 role of, 49-60  
 testing for, 117-121, 206  
 transgenic rat model, 66  
 Humira. See *Adalimumab*.

IBP. See *Inflammatory back pain*.

IL-6, tocilizumab and, 238, 244

IL-17, 18, 19, 61, 253, 254. See also *Biologics targeting IL-17*.  
 anti-IL-17, 17, 19, 256. See also *Secukinumab*.  
 anti-IL-17A  
 ixekizumab, 256  
 secukinumab, 256. See also *Secukinumab*.  
 anti-IL-17RA (broadalumab), 256  
 biologics targeting, 253-276  
 CBP30 and, 19  
 gender and, 253  
 genetic associations, 255  
 HLA-B27 misfolding and, 64  
 IL-17A, 254, 256

IL-22, 19, 253, 254  
 anti-IL-22, 17  
 over-expression of, 16, 18

IL-23, 253, 254  
 antibody to (ustekinumab), 19, 244, 253-256  
 biologics targeting, 244, 253  
 gender and, 253  
 genes, 61, 62-63, 255  
 inflammation and, 18, 19  
 over-expression of, 16-19, 18, 60-61  
 gut microbiome and, 57-60  
 HLA-B27 misfolding and, 64  
 receptor, genes for, 60, 62-63

ILC3 cells, 16

Imaging, 125-146  
 bone scintigraphy, 142  
 CT (computed tomography), 141, 142  
 DEXA scans, 142  
 DISH, differentiating from AS, 125, 130t-131t  
 interpretation of, 150  
 MRI, 126-132  
 in classification criteria, 24, 27, 31t, 81-82  
 combination of spine and SI joints, 135-140  
 early diagnosis with, 150

## Imaging, MRI (continued)

- findings of active inflammation, 133, 135, 137t, 138-139, 140
- findings of chronic spinal changes, 135
- findings of structural damage, 133-135, 137t
- improvements with TNF inhibitors, 231-234
- recommendations for, 127-132, 140, 142
  - for enthesitis, 142, 144-145
- whole body MRI, 140, 141
- radiologic (classification) criteria, 24, 24t-26t
- of sacroiliac (SI) joints/sacroiliitis, 125-140, 127-129, 130t-131t
- sensitivity and specificity of, 125
- of spine, 127, 134-135, 135-140, 163-164, 164
  - bamboo spine, 127, 134-135
- syndesmophytes, 127
- T1 Spin Echo (T1SE), 132-133, 136
- ultrasonography, 141-142, 144-145

## Immobility, avoiding prolonged periods of, 208

## Immune system, 16-19, 18. See also *Interleukins*.

- autoimmunity, 17, 60, 62-63, 66-67
- cell types, 254
- dysregulation in AS, 16, 18
- innate immune response, 67
- innate lymphoid (ILC3) cells, 16
- natural killer (NK) cells, 16, 61
- secukinumab and, 274
- TNF inhibitors and, 238, 253

## Immunoglobulin A, 117

## Indigenous populations, 41-44, 42t-43t

## Indomethacin (Indocin), 201

## Infections

- Candida*, 274
- herpes zoster, 242
- Legionella pneumophila*, 242
- opportunistic, 239t, 240
- secukinumab therapy and, 263, 271t, 273t, 274
- serious, 239t
- TNF inhibitor therapy and, 238-242, 239t
- tuberculosis (TB), 239, 240-241
- vaccinations, 240-241

## Infectious triggers for AS, 66-67, 93t

## Inflammation

- active, MRI findings, 133, 135, 137t, 138-139, 140
- in AS, 13, 14, 85-89
  - as predictor of mortality, 283
- autoinflammation, 17

## Inflammation (continued)

- in axial skeleton, 88
- of gut, 16, 67-68, 99, 254
- IL-23 and, 16-19, 18
- inflammatory genes, 16
- proinflammatory cytokines, 19, 57, 61, 90, 253, 254
- of sacroiliac (SI) joints, 13, 71-72, 85, 92t. See also *Sacroiliitis*.
- of spine, 88
  - TNF inhibitors and, 231
  - in tendons and bursae, 89
- Inflammatory back pain (IBP), 73, 86, 147-148
  - in disease progression, 147
- Inflammatory bowel disease (IBD), 67, 99
  - with AS, treatment recommendations, 182t
  - HLA-B27 association with, 118t
  - NSAIDs and, 202
  - secukinumab and, 263-271
  - treatment, 181, 182t
    - with TNF-inhibitors, 220
- Inflectra (biosimilar for infliximab/Remicade), 230
- Infliximab (Remicade), 222-225
  - biosimilar for (Inflectra), 230
  - costs of, 281
  - dosage and administration, 222, 225, 237t
  - efficacy, 222-225
    - long-term, 222, 224
    - vs secukinumab, 259t
  - indications, inflammatory bowel disease with AS, 182t
  - injection site reactions, 243
  - patient characteristics, 74t-75t
  - TB and other infections, 241
    - Legionella pneumophila*, 242
  - innate lymphoid (ILC3) cells, 16
- Interleukins. See also *Biologics targeting IL-17; specific interleukins, eg, IL-17*.
- biologics targeting, 17
- biologics targeting IL-17, 253-276
  - over-expression of, 16-19, 18
- Ixekizumab (anti-IL17A), 256
- Japanese patients, 119, 120t
- Joint testing maneuvers, 107, 108-109, 150
- Juvenile-onset AS, 95, 118t, 147
  - outcomes with delay in diagnosis, 148
- Juvenile SpA, 92t-93t
  - efficacy of TNF inhibitors SpA, 221

- Ketoprofen (Orudis), 201
- Kidney comorbidities, 96, 100
- Klebsiella bacteria, 66
- Kyphosis, spinal, 88, 90, 102, 134  
spine osteotomy for, 181, 209
- Laboratory findings, 117-124  
CRP, elevated, 117  
disease activity scores (ASDAS), 117  
GI symptoms, 117  
HLA-B27 testing, 117-121  
immunoglobulin A, 117  
lack of specific diagnostic marker, 117
- Lactation, compatible agents, 238
- Leflunamide, 203  
cautions for pregnancy and lactation, 238
- Legionella pneumophila*, 242
- Long-term efficacy of TNF inhibitor therapy, 221, 222, 224, 234, 280-281
- Long-term successful management of AS, 289-292
- Lung comorbidities, 96, 101
- Lung complications, postsurgical, 210
- Lymphoma, TNF inhibitors and, 239t, 242-243
- Malignancies  
secukinumab and, 274  
TNF inhibitors and, 239t, 242-243
- MEASURE 1 trial, 257-261, 258t, 261, 262, 262, 264-265, 266, 268
- MEASURE 2 trial, 257, 258t, 261-262, 267, 269
- MEASURE 3 trial, 262-263
- MEASURE 4 trial, 263
- Mechanical stress, 67, 87
- Medical alert card, 210, 212-213
- Mental health (depression), 171
- Methotrexate (MTX), 203  
as pregnancy- and lactation-compatible, 238
- MFI (Multidimensional Fatigue Inventory), 162
- Microbiome. See *Gut microbiome*.
- Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), 163-164, 164
- Mofetil, 238
- Monitoring of disease activity. See *Assessment and monitoring*.
- Mortality in AS, 282-283
- MRI, 126-132  
in classification criteria, 24, 27, 31t, 150-151  
combination of spine and SI joints, 135-140  
early detection and, 81-82, 150  
findings, as predictor of response to TNF inhibitors, 140  
findings of active inflammation, 133, 135, 137t, 138-139  
findings of structural damage, 133-135, 137t  
NSAID use compatible with, 140  
recommendations for, 127-132, 140, 142  
for enthesitis, 142, 144-145  
whole body MRI, 140, 141
- Multiple sclerosis, 103
- Musculoskeletal manifestations, 85-94
- Mycophenolate, 238
- Nabumetone (Relafen), 202
- Naproxen (Naprosyn), 201
- Narcotics, 205
- National Institute for Health and Care Excellence. See *NICE*.
- Native Americans, prevalence of HLA-B27 in, 41-44, 42t
- Natural killer (NK) cells, 16, 61
- Neck fractures, 90, 102
- Neck pain, new-onset, 210
- Nephropathy, 96, 101
- Neurologic comorbidities, 101, 114-116
- NHANES (National Health and Nutrition Examination Survey), 44-45
- NICE (National Institute for Health and Care Excellence), 295  
approval of secukinumab for treatment of AS, 19, 256
- NLRP2 gene, 67
- Non-genetic factors, 65-67
- Nonbiologic therapy. See *Conventional (nonbiologic) therapy*.
- Nonpharmacologic management, 194-197. See also *Treatment*.  
combined with pharmacologic treatment, 194  
exercise and physical therapy, 195-197  
patient education, 194-195
- Nonradiographic axial spondyloarthritis (nr-axSpA), 15, 27-29, 71  
classification criteria, 27-29  
differences from AS, 72, 74t-75t  
as early stage of axial spondyloarthritis (ax-SpA), 71-72, 80-81  
first terminology, 71  
gender and, 71, 80-81, 235  
heterogeneity of, 81  
patient characteristics, 72, 74t-75t

Nonradiographic axial spondyloarthritis (nr-axSpA)

(continued)

- progression to AS, 15, 29, 73, 80
    - not always an occurrence, 72
  - Th17 cells and, 253
  - treatment recommendations, 15
    - TNF inhibitors, 29, 182t, 183-184, 235-238
      - efficacy, 235-238, 245
      - EMA approval of, 29-31, 217, 220-221, 235
      - not yet approved by FDA, 183, 217
      - use in NSAID-resistant nr-axSpA, 182t, 183
- Nr-axSpA. See *Nonradiographic axial spondyloarthritis*.
- NSAIDs (nonsteroidal anti-inflammatory drugs), 197-202
- agents, 201-202
    - choice of, 201-202
    - combination of, 202
  - cautions, 202
  - continuous vs on-demand treatment, 201
  - dosing, 201
  - efficacy, 197-201
    - effects on radiographic progression, 201
  - GI complications, 202
  - MRI: compatible with MRI imaging, 140
  - NSAID treatment-resistant patients, alternatives for, 182t, 235, 244
  - and prognosis/mortality in AS, 283
  - recommendations for use
    - ACR/SPARTAN recommendations, 197
      - for active AS, 180, 182t
      - ASAS/EULAR recommendations, 177, 197
      - as first-line therapy for AS, 197, 244
      - for stable AS, 181
    - as symptom-modifying anti-rheumatic drugs (SMARDs), 157
- Occiput-to-wall measurement, 113, 115, 159t, 161
- OMERACT, 157-162
- Onset. See *Age of onset*.
- Ophthalmologic issues, 208
- Organizations and resources, 293-295
- Orthopedic referrals, 208
- Osteitis, 13
- Osteitis condensans ilei, 125-126, 132
- Osteopenia, 205
- Osteoporosis, 87, 89-90, 102, 205
- Osteoproliferation, 18, 19, 89-90
  - IL-22 and, 254
- Oxaprozin (Daypro), 201

P300, 19

Pain, 85. See also *Back pain*.

- in AS vs nr-axSpA, 77t
  - assessment, 159t, 161, 165
  - chest wall, 87, 109-111
  - in female patients, 88, 114
  - fractures and, 210
- Paracetamol (acetaminophen), 204-205
- PASS (Patient Acceptable Symptom Scale), 170-171
- Pathogenesis, 13, 15-16, 49-70. See also *Etiology*.
- enthesitis, 14, 87
  - genetics and, 15-16, 49-65
  - gut microbiome, 16, 18, 57-60, 65-66
  - immune dysregulation, 16
  - interaction of genetic and nongenetic factors, 49
  - sequence of events, 14
- Patient concerns and questions, 205-208
- driving automobiles, 207
  - restrictions/disability-related issues, 207-208
- Patient coping mechanisms, 282
- case study (long-term successful management of AS), 289-292
- Patient education, 194-195
- Peripheral joint involvement, 89, 92t, 113-114
- assessment and monitoring, 159t
- Peripheral spondyloarthropathies, 13, 14, 77t
- PGE2, 61
- Pharmacologic therapy, 197-205. See also *Treatment*.
- analgesics and other medications, 204-205
  - biologic therapies
    - IL-17-targeting, 253-276
    - TNF inhibitors, 217-252
  - combined with nonpharmacologic treatment, 194
  - corticosteroids, 204
  - DMARDs, 202-204
  - NSAIDs, 197-202
- Physical activity. See *Exercise*.
- Physical findings, 107-116, 150
- cauda equina syndrome, 96, 103, 116
  - cervical spine, 113, 115
  - chest wall, 109-111
  - enthesitis, 150
  - hip and shoulder joints, 111-113, 113, 114
  - limitations of spinal mobility, 107, 107-109, 198-200
    - Schober's test, 109, 111, 112, 159t
  - neurologic complications, 114-116

- Physical findings (*continued*)
- peripheral joints, 113-114
  - posture, 114
  - SI joint testing, 107, 108-109
  - spinal ankylosis, 114
  - tenderness over joints, 150
- Physical function, 244, 277-278, 282
- assessment and monitoring, 159t, 160-161, 160t
  - assistive devices, 208
  - BASFI, 160-161, 160t
  - disability-related issues, 207-208
  - Dougados Functional Index, 160
  - driving of automobiles, 207
  - older patients, 283
  - prognosis and, 282, 283
  - smoking and, 283
- Physical therapy, 195-197
- core domains for evaluation (ASAS/OMERACT), 157-162, 159t
  - treatment recommendations, 182t, 194, 195-197
    - for active AS, 180, 182t
    - as first-line therapy for AS, 244
    - for stable AS, 181
  - yearly follow-up, 195
- Piroxicam (Feldene), 201
- Pneumococcal vaccination, 240
- Population studies, 35-41, 36t, 37t, 39, 40
- Posture
- functional issues, 208
  - limitations, 198-200
  - physical findings, 114
  - treatment recommendations for, 195, 197
- Pregnancy
- cautions and contraindications, 238, 239t
  - compatible treatments, 238
  - secukinumab and, 274
  - TNF inhibitors and, 238, 239t
- Prevalence of AS/SpA, 35-48
- in the Americas, 44-45
  - in Asian populations, 38, 40, 44
  - criteria used, 35, 36t
  - in European populations, 36t, 37t, 39
  - gender and, 74t, 76t, 80-81, 92t
  - population studies, 35-41, 36t, 37t, 39, 40
  - prevalence of HLA-B27 and, 38, 41-44, 42t-43t
- Prevalence of nr-axSpA, gender and, 71, 72, 76t, 80-81
- Prognosis for AS patients, 282-283
- case study of long-term successful management of AS, 289-292
- Pseudoarthrosis, 209
- case study, 288-289
- Psoriasis, 15, 96, 100
- approved treatment agents
    - ixekizumab (anti-IL-17A), 256
    - secukinumab, 19, 244, 257
    - ustekinumab (anti-IL-23), 19, 256
  - new-onset, TNF inhibitor therapy and, 243
- Psoriatic arthritis (PsA)
- approved treatment agents
    - secukinumab, 19, 244, 257
    - ustekinumab (anti-IL-23), 19, 256
  - clinical features, 92t-93t
  - HLA-B27 association with, 118t
- Pulmonary comorbidities, 96, 101
- Pulmonary complications, postsurgical, 210
- Quality of life, 277. See also *Physical function*.
- activities of daily living, 207-208
  - assessments of, 170
    - AS (ASQoL), 170
    - health related (HRQoL), 170
- Race/ethnicity
- HLA-B27 and, 13, 41, 42t-43t, 52-53, 54, 55
  - worldwide association with SpA, 118, 118t, 119, 120t
  - indigenous populations, 41-44, 42t-43t
- Radiology. See also *Sacroiliitis; specific modalities, e.g., MRI*.
- evidence of sacroiliitis, 13, 24, 24t-26t, 31t, 71, 73
    - grading system for New York Classification Criteria, 125, 126t
    - required for AS definition, 119, 125
    - time of disease progression needed to show, 147-148
  - radiographic progression, hypotheses on relationships of, 278, 280
  - radiologic classification criteria, 24, 24t-26t
- RAPID-axSpA trial, 259t
- Reactive arthritis
- clinical features, 92t-93t
  - HLA-B27 association with, 118t
- Record keeping, 157, 158, 163
- Referrals/consultations, 208
- ophthalmologic issues, 208
  - rheumatology referrals, 121, 151, 152, 208
- Remicade. See *Infliximab*.

Remission criteria, 166-172  
 Resources, 293-295  
 Response and remission criteria, 166-172  
 Rheumatoid arthritis (RA)  
   compared with AS, 15  
   treatment options, 15, 244  
 Rheumatoid factor, 71  
 Rheumatology referrals, 121, 151, 152, 208  
   children of HLA-B27-positive parents, 206-207  
 Rituximab, 244  
   cautions for pregnancy and lactation, 238  
 Rofecoxib (Vioxx), 202

Sacroiliac (SI) joints  
 anatomy of, 128  
 bone marrow edema (BME) scores, 260-261, 264-265  
 complete fusion of, 127, 133  
 imaging of, 125-140, 127-129, 136. See also *MRI*.  
   MRI recommendations, 127-132  
   T1 Spin Echo (T1SE), 132-133, 136  
 inflammation of, 13, 71, 85. See also *Sacroiliitis*.  
 normal, in early AS, 147  
 physical findings, 107  
   pain, 107  
 tenderness, 150  
 testing maneuvers, 107, 108-109, 150  
   FABERE test, 107, 108-109  
 in women: iliac sclerosis (osteitis condensans ileii), 125-126, 132

Sacroiliitis, 71-72, 92t  
 in classification criteria, 24, 24t-26t, 31t  
   radiographic grading system for sacroiliitis, 125, 126t  
 in diagnostic algorithm, 152  
 differentiating DISH from AS, 125, 130t-131t  
 disease progression and, 147  
   time from IBP to, 147-148  
 as predictor of disease progression, 220  
 as predictor of response to therapies, 220  
 radiographic evidence of, 13, 24, 24t-26t, 31t, 71, 73  
   AS vs axSpA patients, 72-80  
   grading system for, 125, 126t  
   imaging examples, 125, 127-129  
   improvements with TNF inhibitors, 231-234  
   modified NY criteria, 71, 72-80, 125, 126t

Sacroiliitis (*continued*)  
 MRI, 125-140, 127-129, 136  
   early detection with, 81-82, 150  
   as predictor of disease progression, 220  
 progression  
   gender and, 81-82  
   hypotheses on relationships of, 278, 280  
   progression to AS, 80  
 T1 Spin Echo (T1SE), 132-133, 136  
 time of disease progression needed to show, 147-148  
 radiographically normal  
   does not rule out AS, 147  
   in early AS/axSpA, 147-149  
 symmetry of, 92t  
 treatment  
   local corticosteroid injections, 204  
   TNF-inhibitors, 231-234

Sarilumab, 244

Schober's test, 88, 109, 111, 112, 159t, 161-162

Secukinumab (Cosentyx)  
 action mechanism, 243, 253, 256  
   as selective anti-IL17/17A (monoclonal antibody), 19, 243, 256  
 adverse reactions, 263-271, 271t, 272t-273t  
   IBD, 263-271  
   infections, 263, 271t, 273t, 274  
 approvals for treatment of AS, 19, 178, 243-244, 256-257  
   EMA, 19, 256  
   FDA, 19, 178, 243-244, 256  
   NICE, 256  
 approvals for treatment of psoriasis and PsA, 19, 178, 244, 257  
 cautions and contraindications, 263-271  
   Crohn's disease, 271  
   IBD, 271  
   live vaccinations, 263  
 clinical trials, 244, 255, 257-263  
   ASSERT, 259t  
   ATLAS, 258t  
   GO-RAISE, 259t  
   MEASURE 1 (AS2), 257-261, 258t, 261, 262, 262, 264-265, 266, 268  
   MEASURE 2, 257, 258t, 261-262, 267, 269  
   MEASURE 3, 262-263  
   MEASURE 4, 263  
   phase 3 trials, 256  
   RAPID-axSpA, 259t  
   summary of, 255

- Secukinumab (Cosentyx) (*continued*)  
 composition/constitution of, 256  
 dose and administration, 275, 275  
 efficacy, 257-263  
 ASAS20 and ASAS40 values, 258t-259t, 260, 261, 262, 266-267, 268-269  
 Berlin Spine Scores, 264-265  
 compared with TNF inhibitors, 244, 256-257, 258t-259t  
 phase 3 trials, 256  
 radiographic progression (mSASSS), 262, 270  
 randomized, controlled trials, 244  
 SI joint bone marrow edema (BME) scores, 260-261, 264-265  
 spinal radiographic progression at week 104, 261  
 time course of response, 260, 262  
 in TNF inhibitor-naïve or intolerant patients, 262, 266-267  
 indications for  
 active AS in adults, 256  
 active AS unresponsive to TNF inhibitors, 19, 178, 244, 257  
 as alternative treatment option for AS, 257  
 pregnancy risk, 274  
 safety and tolerability, 263-274  
 adverse reactions, 263-271, 271t, 272t-273t  
 discontinuation, 271, 272t  
 IBD, 263-271  
 infections, 263, 271t, 273t, 274  
 TB monitoring, 263  
 Shoulder joints, 88-89, 111-113, 114  
 Simponi. See *Golimumab*.  
 Skin manifestations, 96, 100  
 Sleep, 208  
 apnea, 101, 208  
 back pain and, 95  
 firm mattress, 195  
 Slow-acting antirheumatic drugs, 202  
 SMARTDs. See *Symptom-modifying anti-rheumatic drugs*.  
 Smoking, 107, 194-195  
 cessation of, 194-195  
 functional disability and, 283  
 reduced effectiveness of TNF inhibitors, 221  
 Socioeconomic impact of AS, 277-282  
 costs, 277-278, 279t  
 functional disability, 277-278  
 quality of life, 277  
 work productivity and disability, 277-278, 279t  
 SPARTAN (Spondyloarthritis Research and Treatment Network), 81  
 treatment recommendations, 15, 176, 193  
 Spinal mobility  
 assessment of, 159t, 161-162, 162t  
 BASMI, 161, 162t  
 Schober's test, 88, 109, 111, 112, 159t, 161-162  
 exercises for, 197  
 limitations in, 107-109, 113, 198-200  
 loss of, 88  
 Spinal pseudoarthrosis, 209  
 Spine  
 "bamboo spine," 127, 134-135  
 Berlin Spine Scores, with secukinumab, 264-265  
 cervical, 113  
 occiput-to-wall measurement, 113, 115, 159t, 161  
 complete fusion of, 127, 134-135  
 fractures, 90, 101-102, 102, 210  
 imaging of, 142  
 imaging, 127, 134-135, 135-140, 163-164, 164  
 modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), 163-164, 164  
 inflammation, 88  
 TNF inhibitors and, 231  
 kyphosis, 88, 90, 102, 134  
 surgery for, 181  
 mobility of. See *Spinal mobility*.  
 MRI of, 135-140, 138-139  
 osteoporosis, 89-90, 102  
 radiographs, 163-164. See also *Imaging*.  
 stiffness, 162  
 exercise and, 196  
 physical limitations due to, 197, 198-200  
 surgery  
 spinal fusion, 209  
 spinal osteotomy, 181, 209  
 syndesmophytes, 163, 164  
 Spondylitis Association of America (SAA), 295  
 treatment recommendations, 15  
 Spondyloarthritis, 13, 14  
 Spondyloarthritis Research and Treatment Network (SPARTAN), 81  
 treatment recommendations, 15, 176, 193  
 Spondyloarthropathies (SpA). See also *Nonradiographic axial spondyloarthropathy (nr-axSpA)*.  
 axial vs peripheral, 13, 14  
 clinical features, compared to AS, 92t-93t

Spondyloarthropathies (SpA) (*continued*)

- conditions included, 13
- defined, 13
- enteropathic, 92t-93t
- juvenile, 92t-93t
- nonradiographic axial (nr-axSpA), 15
- prevalence of, 35-48
- Sports activities, 196
- Stiffness, 86, 88, 152
  - assessment, 159t, 162
  - as early symptom, 147
  - in paraspinal muscle, 109
  - spinal, 162
- Suicide risk
  - with broadalumab (anti-IL-17RA), 256
  - with secukinumab, 274
- Sulfasalazine (SSZ), 203
  - ASAS/EULAR treatment recommendations, 177
  - etanercept vs., 203
  - as pregnancy- and lactation-compatible, 238
- Sulindac (Clinoril), 202
- Surgery, 209-210
  - anesthesia, 209
  - ASAS/EULAR treatment recommendations, 177
  - hip arthroplasty/replacement, 181, 182t, 209
  - postsurgical complications, 210
  - spine osteotomy, 181, 209
- Swimming, 196-197
- Swiss Ankylosing Spondylitis Association (SVMB), 293
- Symptom-modifying anti-rheumatic drugs (SMARDs)
  - core domains for evaluation (ASAS/OMERACT), 157-162, 159t
  - NSAIDs, 157
- Symptoms, 13, 23, 71-72. See also *specific symptoms*.
  - of active disease, 157
  - age of onset, 85-86, 87
  - back pain, 15, 73, 85-86, 147
    - in classification criteria, 23, 24t, 25t, 26t, 28t-29t, 30t, 31t
  - early, nonspecific nature of, 147
  - extra-articular, 95-106, 96
  - fatigue, 95, 159t
  - inflammatory back pain, 147-148
  - musculoskeletal, 85-94
  - Patient Acceptable Symptom Scale (PASS), 170-171
  - stiffness, 86, 88, 147, 152
- Syndesmophytes, 107, 127, 163, 164
- T-Cell lymphoma, 243
- T helper 17 (Th17) cells, 253, 254
- T1 Spin Echo (T1SE), 132-133, 136
- Tacrolimus, 238
- Tendons, 89
- Thalidomide, 203
- Therapy. See *Treatment*.
- 3E (Evidence, Experts, Exchange) Initiative, 193-194
- TNF- $\alpha$  (tumor necrosis factor-alpha), actions, 16, 19
- TNF inhibitor therapy, 217-252. See also *specific agents*.
  - administration modes, 220
  - adverse effects. See *subentry for "untoward effects" below*.
  - agents, 217. See also *specific agents*.
    - adalimumab (Humira), 217, 225-227
    - biosimilars, 230-231
    - certolizumab pegol (Cimzia), 217
    - choice of, 220
    - etanercept (Enbrel), 217, 222
    - golimumab (Simponi), 217, 227
    - infliximab (Remicade), 217, 222-225
    - switching between, 234
  - approved indications
    - FDA and EMA approvals, 217, 220-221
    - treatment of active AS in adults unresponsive to other therapies, 217, 235
    - treatment of nr-axSpA (nonradiographic axial spondyloarthropathy) (EMA approval), 29-31, 217, 220-221, 235
  - biologic therapy beyond, 243-244
  - biosimilars, 230-231
    - Amjevits (for adalimumab/Humira), 231
    - Erelzi (for etanercept/Enbrel), 231
    - FDA approval of, 230-231
    - Inflectra (for infliximab/Remicade), 230
  - bone density increased with, 231, 234
  - cautions and contraindications, 237t, 238-243, 239t
    - pregnancy, 238
  - choice of agents, 220
  - concluding remarks, 244-245
  - cost-effectiveness of, 280-282
  - discontinuation of, 221, 234
  - as disease-controlling anti-rheumatic treatment (DC-ART), 157
  - dosing, 237t. See also *specific agents*.
    - dose reduction, 221, 225

TNF inhibitor therapy (*continued*)

efficacy, 220-234, 244-245

- ASAS response criteria and, 168-169, 221, 222
- compared with secukinumab (Cosentyx), 244, 256-257, 258t-259t
- decrease in, 221
- early use in disease course, 169, 217, 245
- improvements observed on imaging, 231-234
- juvenile SpA, 221
- long-term, 221, 234, 280-281
- monotherapy, 220
- for nr-axSpA, 235-238, 245
- obese and overweight patients, 221
- secukinumab vs, 244
- smokers, 221
- of specific agents, 222-230
- for treatment of IBD, 220

EMA (European Medicines Agency) approvals, 29-31, 217, 220-221

history of, 217

IL-23 and, 16

monoclonal antibodies, 217

- effective for treatment of IBD, 220

MRI findings as predictor of clinical response to, 140

patient characteristics, AS vs nr-axSpA, 72, 74t-75t, 78t

safety issues, 237t, 238-243, 239t

- infections, 238-242, 239t
- malignancies, 242-243

sleep problems and, 85

treatment algorithm, 218-219

treatment recommendations

- for active AS, 180, 182t, 217, 218-219
- for active nr-axSpA, 182t, 217, 235

ASAS consensus statement, 217, 218-219, 234

ASAS/EULAR recommendations, 177, 193

- no threshold values for BASDAI or ASDAS scores, 193

criteria for AS and, 217, 221, 245

early use in disease progression, 169, 217

EMA approvals, 29-31, 217, 220-221

guidelines for use in AS, 218-219, 234, 236t-237t

initiation of treatment, 234

- for NSAID-resistant AS, 182t, 183-184, 244

outdated information on, 178, 180-181

- for stable AS, 181

switching agents, 234

treatment response criteria (BASDAI, ASDAS), 166-172, 234, 237t

TNF inhibitor therapy (*continued*)

untoward effects, 238-243, 239t

- immune impairment, 238, 253
- infections, 238-242, 239t
- injection site reactions, 243
- malignancies, 242-243
- new-onset psoriasis, 243
- tuberculosis (TB), 239, 240-241, 253
- vaccinations recommended, 240-241

Tocilizumab (anti-IL-6), 244

- cautions for pregnancy and lactation, 238

Tofacitinib, 238

Tolmetin (Tolectin), 201

Tramadol, 204-205

Treatment. See also *specific agents and classes of agents*.

- biologic therapies, 217-276. See also *Secukinumab*.
  - targeting IL-17, 253-276
    - secukinumab, 256-275. See also *Secukinumab*.
  - targeting IL-23, 244, 253-256
  - TNF inhibitors, 217-252
- bromodomain inhibition of CBP/p300, 19
- conventional (nonbiologic) therapy, 193-216. See also *Conventional (nonbiologic) therapy*.
  - 3E Initiative recommendations, 193-194
  - nonpharmacologic management, 194-197
    - combined with pharmacologic treatment, 194
    - exercise and physical therapy, 195-197
    - patient education, 194-195
  - patient concerns and questions, 205-208
  - pharmacologic therapy, 197-205. See also *Pharmacologic therapy*.
    - analgesics, 204-205
    - biologic therapies, 217-276
    - combined with nonpharmacologic treatment, 194
    - corticosteroids, 204
    - surgery, 209-210
- corticosteroids/glucocorticoids, 177, 180, 182t, 204
- costs
  - of anti-TNF therapy, 280-282
  - reduction with treatment, 278
- disease-controlling anti-rheumatic treatment (DC-ART), 158, 163-164
- early diagnosis and, 82, 148
- epigenetic inhibitors, 19
- FDA-approved, 19

Treatment (*continued*)

- goals of, 193
- individualized, 193-194
- monitoring disease activity and, 157, 168-169
- NSAIDs, 177
- progress in treatment options, 15
- recommendations/guidelines, 15, 175-191
  - 3E (Evidence, Experts, Exchange) Initiative, 193-194
  - ACR, 175
  - ASAS/EULAR, 175-176, 177, 193
  - country-specific, 176-178, 193
  - GRADE system, 176, 178, 179t
  - secukinumab approval for AS, 178
  - SPARTAN, 15, 176, 193
  - strength of recommendations, 178, 179t, 182t
  - summary/flow chart, 177
  - summary for active AS, 180, 182t
  - summary for stable AS, 181
  - TNF $\alpha$  inhibitors, 176, 177, 218-219, 234, 236t-237t
    - outdated data on, 178, 180-181
  - treat-to-target principle, 184, 185, 186t-189t
  - US-specific, 176-178, 193
- response and remission criteria, 166-172, 234, 237t
- sulfasalazine, 177
- surgery, 177, 181, 209-210
- symptom-modifying anti-rheumatic drugs (SMARDs)
  - ASAS/OMERACT core domains, 157-162, 159t
  - NSAIDs, 157
- TNF inhibitor therapy, 217-252
  - agents, 217, 222-230
  - ASAS/EULAR recommendations, 176, 177, 218-219
  - conclusions on, 244-245
  - cost-effectiveness of, 280-282
  - efficacy, 220-230, 222-234, 244-245
  - guidelines for use in AS, 218-219, 234, 236t-237t
    - outdated information on, 178, 180-181
  - response criteria, 166-172, 234, 237t
  - treatment algorithm, 218-219
  - untoward effects and safety issues, 237t, 238-243, 239t
  - treat-to-target principle, 184, 185, 186t-189t
- Tuberculosis (TB), 239, 240-241
  - monitoring prior to initiating secukinumab, 263
- Tumor necrosis factor-alpha. See *TNF- $\alpha$* .
- Tumor necrosis factor inhibitors. See *TNF inhibitor therapy*.
- Turkey, prevalence of AS in, 35-38, 36t, 37t
- Twin studies, 49
- Ulcerative colitis (UC), 60, 65, 96
- Ultrasonography, 141-142, 144-145
- Unfolded protein response (UPR), 57, 58-59, 64, 65, 66
- UPR. See *Unfolded protein response*.
- US Food and Drug Administration (FDA), 274, 294
- Ustekinumab (anti-IL-23), 19, 244, 263-266
  - action mechanism (anti-IL-23 antibody), 244
  - approved indications, CD, 256
    - psoriasis and PsA, 19, 256
  - cautions for pregnancy and lactation, 238
  - chemical composition, 244
  - clinical trials
    - phase 3 studies in AS, 244, 256
    - summary of, 255
- Uveitis. See also *Acute anterior uveitis*.
  - acute anterior uveitis (AAU), 95-99, 96, 97
  - secukinumab and, 274
- Vaccinations, 240-241
  - cautions for, 263
- Visual analogue scale (VAS), 165
- Vitamin D, 90, 205
- Walking aids, 208
- Women
  - atypical AS presentation in, 151
  - diagnosis in, 148, 149, 151
    - delay of diagnosis, 86-87, 148, 149, 151
  - iliac sclerosis in (osteitis condensans ileii), 125-126, 132
  - pain in, 88, 114
  - prevalence of n-axSpA (nonradiographic axial spondyloarthritis), 71, 72, 80-81, 235
  - progression to radiographic sacroiliitis, 81-82
  - speed of disease progression, 86-87, 88, 114, 151
- Work disability, 277-278
  - as predictor of mortality in AS, 283
- Work productivity
  - assessments, 171-172
  - decline in, 277-278, 279t, 281
- Workplace modifications, 194
- Zoster vaccination, 240-241